STENTYS Reports 40% Increase in Revenues in Second Quarter of 2015
STENTYS (Paris:STNT) (FR0010949404 - STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces its revenues and cash position at June 30, 2015.
- Quarterly revenues*
|Half year – 6 months||Quarter – 3 months|
|€ thousands||H1 2015||H1 2014||Var. %||Q2 2015||Q2 2014||Var. %|
* Figures subject to a limited review
Following a promising first quarter (with sales up 28%), STENTYS continues on its growth momentum with revenues increasing by 40% to €1.5 million in the second quarter of 2015. This acceleration is the result of the launch of the Xposition® product line, STENTYS' new generation of self-apposing stent, during the month of May 2015. Combining the Sirolimus-eluting stent and the new delivery catheter that replicates the implantation technique of a conventional stent, Xposition has been well received by cardiologists.
Over the first half of 2015, STENTYS recorded sales of €2.6 million, a 34.7% increase.
- Sound cash position
At June 30, 2015, STENTYS' balance sheet remained solid with cash and equivalents of €12.7 million.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: "The launch of the Xposition line is progressing as planned. Our customers are delighted with the improvements to our product and we are very confident that the technology's adoption will continue and our growth will accelerate."
- Upcoming financial report
STENTYS expects to publish its financial results for the first half of 2015 on September 17, 2015.
STENTYS is listed on Comp. C of the Euronext Paris market
ISIN: FR0010949404 – Ticker: STNT